A Phase 1b/2 Randomised, Placebo-controlled, Dose-ranging Study to Evaluate Safety, Tolerability and Immunogenicity of a Chimpanzee Adenovirus (ChAdOx1)-vectored Multigenotype High Risk Human Papillomavirus (hrHPV) Vaccine and Modified Vaccinia Ankara (MVA)-vectored Multigenotype hrHPV Vaccine in Women with Low-grade HPV-related Cervical Lesions - Prime-boost Vaccine Study in Women with Low-grade Cervical HPV Lesions

Vaccitech UK Ltd.0 个研究点目标入组 105 人开始时间: 2020年6月9日最近更新: 2024年5月6日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 105

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: Female

入选标准

•Participants must meet all the following criteria to be eligible for the study:
•1. Females aged =25 and =55 years of age at screening.
•2. Persistent hrHPV infection defined as a documented cervical infection with hrHPV type(s) in the 6 to 18 months prior to screening and confirmed at screening (participants in the main and expansion phases only). Participants in the lead in phase are only required to have the screening result.
•3. Low-grade cervical lesion (CIN1 or HPV related change only) confirmed by histology and/or cytology report within the 1 year prior to screening.
•4. Not pregnant or breast feeding and one of the following:
•Of non-childbearing potential (i.e. women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses for at least 12 months and without an alternative medical cause)
•Of childbearing potential but agrees to practice highly effective contraception for 4 weeks prior to administration of the first dose of study vaccine and throughout the study until 8 weeks after administration of the second dose. Highly effective methods of contraception include one or more of the following:
•- Male partner who is sterile (medically effective vasectomy) prior to the female participant’s entry into the study and is the sole sexual partner for the female participant
•- Hormonal (oral, intravaginal, transdermal, implantable or injectable). Progestogen-only hormonal contraceptives without inhibition of ovulation are not considered to be highly effective.
•- An intrauterine hormone-releasing system
•- An intrauterine device
•- Bilateral tubal occlusion
•- Sexual abstinence, only if the participant refrains from heterosexual intercourse during the entire study period and it is the usual lifestyle of the participant
•5. Willing to abstain from sexual activity for 48 hours prior to all swabbing procedures.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 105
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•Participants who meet any of the following criteria are not eligible for the study:
•1. Presence of any significant acute or chronic, uncontrolled medical (or psychiatric) illness, including blood dyscrasias.
•2. Immunosuppression as a result of underlying illness or treatment including:
•Use of high dose corticosteroids (>10 mg/day prednisone or equivalent) for =7 days (inhaled, otic and ophthalmic corticosteroids are permitted)
•Primary immune deficiency disease
•Use of synthetic or biologic disease-modifying antirheumatic drugs
•History of bone marrow or solid organ transplant
•History of any other clinically significant autoimmune or immunosuppressive disease
•3. Positive diagnostic tests (for human immunodeficiency virus, hepatitis B or hepatitis C) indicating chronic infection.
•4. Evidence of high-grade cervical lesions by colposcopy or by Pap smear test in the 1 year prior to screening.
•5. Any history of anaphylaxis in reaction to vaccination or history of allergic reactions likely to be exacerbated by any component of the vaccine, e.g. severe allergy to eggs.
•6. Receipt of any investigational drug or investigational vaccine within 3 months prior to administration of ChAdOx1-HPV on Day 0, or prior participation in a clinical study of any HPV vaccine.
•7. Receipt of any adenoviral-based vaccine within 3 months prior to administration of ChAdOx1-HPV on Day 0, or plan to receive an adenoviral-based vaccine within 3 months after Day 0.
•8. Receipt of any live vaccines within the 30 days or inactivated vaccine within the 14 days prior to administration of ChAdOx1 HPV on Day 0 or planned to occur in the 2 months after the Day 0 vaccination.
•9. Current or history of illicit drug use within the 6 months prior to screening.
•10. Current or history of severe alcohol abuse within the 6 months prior to screening.
•11. Any laboratory test which is abnormal and deemed by the Investigator to be clinically significant which will potentially affect the participation in the study.
•12. Current known infection with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2).
•13. Any other finding that, in the opinion of the Investigator, deems the participant unsuitable for the study.

研究者

发起方

Vaccitech UK Ltd.

相似试验

进行中（未招募）

1 期

An early phase study of 2 experimental vaccines vs dummy vaccines for the treatment of HPV (Human Papillomavirus) in women with low grade cervical lesions to determine the best dose, effectiveness and safety of the vaccines.

EUCTR2019-001890-98-GBVaccitech Ltd.105

进行中（未招募）

不适用

A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control - N/AType 2 Diabetes Mellitus

EUCTR2010-022193-13-HUMerck Sharp & Dohme Corp. a subsidiary of Merck &Co., Inc600

进行中（未招募）

1 期

EUCTR2010-022193-13-FIMSD Finland Oy600

进行中（未招募）

1 期

EUCTR2010-022193-13-LTMerck Sharp & Dohme Corp.663

进行中（未招募）

不适用

A Phase IIb, Randomized, Placebo-Controlled, Dose-Ranging Study of MK-5442 in the Treatment of Postmenopausal Women with OsteoporosisOsteoporosis

EUCTR2009-012926-35-GBMerck & Co, Inc.384